Abstract
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Kai Yu, Yu-Yi Chu, Sajith Nair, Emanuele Crupi, Elshad Hasanov, Ying Mei, Xueshuai Han, Guangsheng Pei, Fuduan Peng, Jianlong Liao, Enyu Dai, Tian Chu, Kyung Serk Cho, Yibo Dai, Baifeng Zhang, Giannicola Genovese, Nagireddy Putluri, Livia S. Eberlin, Chunru Lin, Lawrence N. Kwong, Diana Shamsutdinova, Khalida M. Wani, Bogdan A. Czerniak, Charles C. Guo, Donna Hansel, Curtis Pettaway, Louis Pisters, Kelly Bree, Neema Navai, Byron H. Lee, Ashish M. Kamat, Padmanee Sharma, Paul Corn, Cindy Y. Jiang, Amishi Y. Shah, Omar Alhalabi, Arlene O. Siefker-Radtke, Christopher J. Logothetis, Matthew T. Campbell, Jianjun Gao
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
10.3322/caac.21834 · 2024
The global burden of urinary bladder cancer: an update
10.1007/s00345-019-02984-4 · 2020
Epidemiology and risk factors of urothelial bladder cancer
10.1016/j.eururo.2012.07.033 · 2013
Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients
10.1200/jco.2001.19.3.666 · 2001
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer
10.1056/nejmoa022148 · 2003
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study
10.1200/jco.2000.18.17.3068 · 2000
Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer
10.1056/nejmoa2408154 · 2024
Perioperative enfortumab vedotin and pembrolizumab in bladder cancer
10.1056/nejmoa2511674 · 2026
A consensus molecular classification of muscle-invasive bladder cancer
10.1016/j.eururo.2019.09.006 · 2020
Comprehensive molecular characterization of urothelial bladder carcinoma
10.1038/nature12965 · 2014
Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade
10.1016/j.ccell.2024.10.016 · 2024
Enfortumab vedotin in previously treated advanced urothelial carcinoma
10.1056/nejmoa2035807 · 2021
Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer
10.1056/nejmoa2312117 · 2024
Intrinsic subtypes and bladder cancer metastasis
10.1016/j.ajur.2016.09.009 · 2016
The origin and evolution of bladder cancer stem cells
10.3389/fcell.2022.950241 · 2022
Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy
10.1016/j.ccr.2014.01.009 · 2014
Comprehensive molecular characterization of muscle-invasive bladder cancer
10.1016/j.cell.2017.09.007 · 2017
Urothelial cancer stem cells and epithelial plasticity: current concepts and therapeutic implications in bladder cancer
10.1007/s10555-015-9589-6 · 2015
Cancer cell plasticity during tumor progression, metastasis and response to therapy
10.1038/s43018-023-00595-y · 2023
Tumor heterogeneity and consequences for bladder cancer treatment
10.3390/cancers13215297 · 2021
Mechanisms and implications of epithelial cell plasticity in the bladder
10.1038/s41585-025-01066-y · 2026
Epithelial plasticity can generate multi-lineage phenotypes in human and murine bladder cancers
10.1038/s41467-020-16162-3 · 2020
FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation
10.1038/s41467-022-34251-3 · 2022
Loss of UTX/KDM6A and the activation of FGFR3 converge to regulate differentiation gene-expression programs in bladder cancer
10.1073/pnas.2008017117 · 2020
Spatial omics and multiplexed imaging to explore cancer biology
10.1038/s41592-021-01203-6 · 2021
Exploring tissue architecture using spatial transcriptomics
10.1038/s41586-021-03634-9 · 2021
Integrating single-cell and spatial transcriptomics to elucidate intercellular tissue dynamics
10.1038/s41576-021-00370-8 · 2021
Single-cell multi-stage spatial evolutional map of esophageal carcinogenesis
10.1016/j.ccell.2025.02.009 · 2025
Spatial cellular architecture predicts prognosis in glioblastoma
10.1038/s41467-023-39933-0 · 2023
Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancer
10.1038/s41588-024-01998-y · 2025
Integrative spatial analysis reveals tumor heterogeneity and immune colony niche related to clinical outcomes in small cell lung cancer
10.1016/j.ccell.2025.01.012 · 2025
Integrated single-cell and spatial transcriptomic profiling reveals higher intratumour heterogeneity and epithelial–fibroblast interactions in recurrent bladder cancer
10.1002/ctm2.1338 · 2023
The potential crosstalk between tumor and plasma cells and its association with clinical outcome and immunotherapy response in bladder cancer
10.1186/s12967-023-04151-1 · 2023
Single-nucleus and spatially resolved intratumor subtype heterogeneity in bladder cancer
10.1016/j.euros.2023.03.006 · 2023
Transcriptional state dynamics lead to heterogeneity and adaptive tumor evolution in urothelial bladder carcinoma
10.1038/s42003-023-05668-3 · 2023
An N-Cadherin 2 expressing epithelial cell subpopulation predicts response to surgery, chemotherapy and immunotherapy in bladder cancer
10.1038/s41467-021-25103-7 · 2021
Robust decomposition of cell type mixtures in spatial transcriptomics
10.1038/s41587-021-00830-w · 2022
Spatially resolved clonal copy number alterations in benign and malignant tissue
10.1038/s41586-022-05023-2 · 2022
Single-cell transcriptional diversity is a hallmark of developmental potential
10.1126/science.aax0249 · 2020
The single-cell transcriptional landscape of mammalian organogenesis
10.1038/s41586-019-0969-x · 2019
Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study
10.1093/oncolo/oyaf342 · doi-reference
Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin
10.1158/1078-0432.ccr-20-4175 · doi-reference
Enfortumab vedotin antibody–drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models
10.1158/0008-5472.can-15-1313 · doi-reference
Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study
10.1200/jco.18.01148 · doi-reference
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
10.1038/s41591-019-0628-7 · doi-reference
NAMPT-driven M2 polarization of tumor-associated macrophages leads to an immunosuppressive microenvironment in colorectal cancer
10.1002/advs.202303177 · doi-reference
MIF-dependent control of tumor immunity
10.3389/fimmu.2020.609948 · doi-reference
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation–a target for novel cancer therapy
10.1016/j.ctrv.2017.11.007 · doi-reference
CXCL13 shapes tertiary lymphoid structures and promotes response to immunotherapy in bladder cancer
10.1016/j.ejca.2021.03.054 · doi-reference
IL-17–induced CXCL12 recruits B cells and induces follicle formation in BALT in the absence of differentiated FDCs
10.1084/jem.20131737 · doi-reference
CXCR5- and CCR7-dependent lymphoid neogenesis in a murine model of chronic antigen-induced arthritis
10.1002/art.22939 · doi-reference
Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance
10.1038/s41591-023-02371-y · doi-reference
Reversing T-cell exhaustion in cancer: lessons learned from PD-1/PD-L1 immune checkpoint blockade
10.1158/2326-6066.cir-21-0515 · doi-reference
Mature tertiary lymphoid structures are key niches of tumour-specific immune responses in pancreatic ductal adenocarcinomas
10.1136/gutjnl-2022-328697 · doi-reference
Ubiquitin-like molecule ISG15 acts as an immune adjuvant to enhance antigen-specific CD8 T-cell tumor immunity
10.1038/mt.2015.120 · doi-reference
Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer
10.1080/2162402x.2017.1378844 · doi-reference
Germinal centers determine the prognostic relevance of tertiary lymphoid structures and are impaired by corticosteroids in lung squamous cell carcinoma
10.1158/0008-5472.can-17-1987 · doi-reference
Mature tertiary lymphoid structures indicate good chemotherapy response and prognosis in advanced colorectal cancer
10.1002/ags3.70142 · doi-reference
Tertiary lymphoid structures predict survival and response to neoadjuvant therapy in locally advanced rectal cancer
10.1038/s41698-024-00533-w · doi-reference
Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2-negative breast cancer
10.1002/cac2.12447 · doi-reference
Heterogeneity of tertiary lymphoid structures predicts the response to neoadjuvant therapy and immune microenvironment characteristics in triple-negative breast cancer
10.1038/s41416-024-02917-y · doi-reference
Tertiary lymphoid structures in anticancer immunity
10.1038/s41568-024-00728-0 · doi-reference
Co-activation of super-enhancer-driven CCAT1 by TP63 and SOX2 promotes squamous cancer progression
10.1038/s41467-018-06081-9 · doi-reference
FOXA1, GATA3 and PPARɣ cooperate to drive luminal subtype in bladder cancer: a molecular analysis of established human cell lines
10.1038/srep38531 · doi-reference
Single-cell and spatial mapping identify cell types and signaling networks in the human ureter
10.1016/j.devcel.2022.07.004 · doi-reference
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
10.1038/nrclinonc.2018.8 · doi-reference
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
10.1038/s41392-023-01705-z · doi-reference
TGF-β signaling in the tumor metabolic microenvironment and targeted therapies
10.1186/s13045-022-01349-6 · doi-reference
Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology
10.1073/pnas.1318376111 · doi-reference
High overall copy number variation burden by genome-wide methylation profiling holds negative prognostic value in surgically treated pancreatic ductal adenocarcinoma
10.1016/j.humpath.2023.11.002 · doi-reference
Germline copy number variants are not associated with globally acquired copy number changes in familial breast tumours
10.1007/s10549-012-2024-6 · doi-reference